Altria yields 6% at a forward P/E of 13, while Pfizer tops the group with a 7% yield backed by solid earnings coverage.
AT&T raised its quarterly dividend 20% after 16 consecutive flat quarters and targets $45 billion in total shareholder returns through 2028.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today.
Retirees rebuilding income streams amid the current interest rate environment need dividend payers with cash-flow durability, not yield traps. The five names below span tobacco, telecom, pharma, and asset management, and each brings a distinct income thesis backed by tool-verified payout data as of July 14, 2026. One caveat up front: Philip Morris International is domiciled in Switzerland, so US investors typically face a 15% Swiss withholding tax on dividends (usually recoverable in taxable accounts via the foreign tax credit, but not in IRAs).
24/7 Wall St.
Altria (MO)
MO Analyst Ratings — 24/7 Wall St.
Altria (NYSE:MO) yields 5.67% at a recent price of $74.82, with a most recent declared quarterly dividend of $1.06 per share, paid on July 10. The stock has climbed 27.42% over the past year.
The bull case is dividend durability paired with earnings momentum. Altria reaffirmed FY2026 adjusted diluted EPS guidance of $5.56 to $5.72, and Q1 2026 delivered adjusted diluted EPS of $1.32 on revenue of $5.43 billion. The smokeable segment still throws off 65.1% margins, funding $1.8 billion in Q1 dividends and buybacks. Forward P/E sits at just 13.
Risk: Marlboro retail share slipped 1.4 points to 39.7%, on! nicotine pouch share fell 4.2 points to 13.4%, and domestic cigarette volumes declined roughly 5%. Long-term volume erosion is the structural headwind pricing power must keep outrunning.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today.
Philip Morris International (PM)
PM Analyst Ratings — 24/7 Wall St.
Philip Morris International (NYSE:PM) yields 2.94% — lower than the others on this list — but its dividend is compounding the fastest. The most recent declared quarterly payout is $1.47, paid on July 20, up from $1.35 in the first half of 2025.
The thesis is a growth-plus-income hybrid built on smoke-free products. PM guided FY2026 adjusted diluted EPS of $8.36 to $8.51, a 10.9%–12.9% jump, and targets a 9%–11% CAGR through 2028 ex-currency. IQOS reaches 108 markets, ZYN reaches 58 markets, and smoke-free is roughly 41.5% of revenue. Analyst target: $194.86.
Risk: Q1 ZYN shipments fell 23.5% on distributor destocking, and PM has paused buybacks to prioritize deleveraging. Add the Swiss withholding wrinkle for taxable-account investors.
AT&T (T)
T Analyst Ratings — 24/7 Wall St.
AT&T (NYSE:T) just gave income investors a rare piece of good news: the quarterly dividend was raised to 33 cents per share, ex-date July 17, payable Aug. 3. That works out to an annualized forward rate of $1.3376, a 20.4% increase off the 27-cent rate that had held for 16 straight quarters.
The bull case is converged fiber-plus-5G economics finally translating to cash. AT&T reaffirmed FY2026 free cash flow of $18 billion or more, plans roughly $8 billion in 2026 buybacks, and targets $45 billion in total shareholder returns from 2026 to 2028. Q1 EPS came in at 57 cents, up 11.8% year-over-year, and the payout ratio remains conservative at roughly half of 2025 reported EPS of $2.11.
Risk: Total debt sits at $138.4 billion, with net debt/EBITDA expected to rise toward 3.2x after the EchoStar transaction. Shares are still down 16.35% over the past year.
Pfizer (PFE)
PFE Analyst Ratings — 24/7 Wall St.
Pfizer (NYSE:PFE) is the ultra-high-yield pick here, sporting a 6.81% dividend yield at roughly $25.25. The most recent quarterly dividend of 43 cents went ex on July 24, and pays out on Sept. 1.
Q1 2026 showed the earnings recovery investors need to underwrite this yield: adjusted diluted EPS of 75 cents on revenue of $14.45 billion, up 5.4% year-over-year. Management reaffirmed FY2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, which comfortably covers the $1.72 annualized dividend. Vyndamax U.S. exclusivity was extended to June 2031, and forward P/E of 8 discounts a lot of bad news.
Risk: COVID revenue is collapsing (Comirnaty down 59%, Paxlovid down 63%), and management flagged a $1.5 billion 2026 revenue headwind from loss of exclusivity. Most-Favored-Nation drug pricing remains an open policy risk.
T. Rowe Price (TROW)
TROW Analyst Ratings — 24/7 Wall St.
T. Rowe Price (NASDAQ:TROW) yields 4.27%, with the current quarterly dividend at $1.30, last paid on June 29. Dividend history in the record shows increases in every calendar year going back to at least 1999, with no cuts across that span.
The bull case is a debt-free balance sheet with $3.73 billion in cash supporting a Dividend Aristocrat payout. Q1 2026 adjusted EPS beat expectations at $2.52 versus $2.35 estimated, a 7.234% surprise, with revenue of $1.86 billion and average AUM of $1.78 trillion, up 9.6% year-over-year. The company returned $629 million to shareholders in Q1.
Risk: Persistent net client outflows totaled $13.7 billion in Q1 2026 and $56.9 billion for FY2025, and fee rates compressed to 38.4 basis points. Analyst sentiment is cool: nine Hold ratings, one Sell rating and three Strong Sell ratings with a 12-month price target of $106.33 (notably below the current share price of $121.68). Retirees buying today are paying for durability, not near-term upside.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today.
Contact editorial@247wallst.com for any questions or corrections.
